69
Participants
Start Date
June 30, 2015
Primary Completion Date
January 28, 2016
Study Completion Date
February 10, 2016
Rifampicin
Participants with body weight \</= 50kg were administered one 450 mg tablet orally once daily. Participants with body weight \>50kg were administered one 600 mg tablet orally once daily.
Isoniazid
Participants were administered three 100 mg tablets or one 300 mg tablet once daily.
Pyrazinamide
Participants with a body weight of 40-55 kg were administered two 500 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 500 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 500 mg tablets orally once daily.
Ethambutol
Participants with a body weight of 40-55 kg were administered two 400 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 400 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 400 mg tablets orally once daily.
Moxifloxacin
Participants were administered one 400 mg tablet orally once a day.
TASK Applied Science CRS (31718), Bellville
University of Cape Town Lung Institute (UCTLI) CRS (31792), Cape Town
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NETWORK